LIVIVO - Search results -

Search results

Result 1 - 10 of total 48

Search options

Book ; Online: Periphere T-Zell Lymphome

Hopfinger, Georg / Herling, Marco / De Leval, Laurence / Krasniqi, Fatime / Reimer, Peter / Schmitz, Norbert / Wulf, Gerald

Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

(Onkopedia Leitlinien)

2021

Abstract: Periphere T-Zell Lymphome (PTCL) sind sehr oft aggressiv verlaufende Lymphome mit dem Phänotyp reifer post-thymischer T- und NK-Zellen und mit primär nodalen oder extranodalen Manifestationen. PTCL machen in Europa ca. 10% aller neu diagnostizierten Non- ... ...

Institution	Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie Schweizerische Gesellschaft für Medizinische Onkologie Schweizerische Gesellschaft für Hämatologie
Author's details	DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., OeGHO - Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie, SSMO/SSOM/SGMO - Schweizerische Gesellschaft für Medizinische Onkologie, SGH-SSH - Schweizerische Gesellschaft für Hämatologie/Société Suisse d'Hématologie ; Autoren:: Georg Hopfinger, Marco Herling, Laurence de Leval, Fatime Krasniqi, Peter Reimer, Norbert Schmitz, Gerald Wulf
Series title	Onkopedia Leitlinien
Abstract	Periphere T-Zell Lymphome (PTCL) sind sehr oft aggressiv verlaufende Lymphome mit dem Phänotyp reifer post-thymischer T- und NK-Zellen und mit primär nodalen oder extranodalen Manifestationen. PTCL machen in Europa ca. 10% aller neu diagnostizierten Non-Hodgkin Lymphome aus. Männer sind häufiger betroffen als Frauen. Der Anspruch der systemischen Primärtherapie ist kurativ, bei den häufigeren Entitäten muss unter der typischen Erstlinientherapie in ca. 30% der Fälle mit einem primär refraktären Verlauf gerechnet werden. Das Ansprechen auf eine Folgetherapie ist meist schlecht, weswegen eine Behandlung in Studien zu empfehlen ist.
Subject code	610
Language	German
Size	1 Online-Ressource (24 Seiten), Diagramme
Edition	Stand: Juni 2021
Publisher	DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V
Publishing place	Berlin
Publishing country	Germany
Document type	Book ; Online
HBZ-ID	HT021153389
DOI	10.4126/FRL01-006430445
Database	Repository for Life Sciences

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Periphere T-Zell Lymphome

Hopfinger, Georg / Herling, Marco / Krasniqi, Fatime / Reimer, Peter / Schmitz, Norbert / Wulf, Gerald

Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD-10 C84.-

(Onkopedia Leitlinien)

2019

Abstract: Periphere T-Zell Lymphome (PTCL) sind klinisch meist aggressiv verlaufende Lymphome mit dem Phänotyp reifer post-thymischer T- und NK-Zellen und primär nodalen oder extranodalen Manifestationen. PTCL machen in Europa ca. 10% aller neu diagnostizierten ... ...

Institution	Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie Schweizerische Gesellschaft für Medizinische Onkologie Schweizerische Gesellschaft für Hämatologie
Author's details	DGHO - Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V., OeGHO - Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie, SSMO/SSOM/SGMO - Schweizerische Gesellschaft für Medizinische Onkologie, SGH-SSH - Schweizerische Gesellschaft für Hämatologie/Société Suisse d'Hématologie ; Autoren: Georg Hopfinger, Marco Herling, Fatime Krasniqi, Peter Reimer, Norbert Schmitz, Gerald Wulf
Series title	Onkopedia Leitlinien
Abstract	Periphere T-Zell Lymphome (PTCL) sind klinisch meist aggressiv verlaufende Lymphome mit dem Phänotyp reifer post-thymischer T- und NK-Zellen und primär nodalen oder extranodalen Manifestationen. PTCL machen in Europa ca. 10% aller neu diagnostizierten Non-Hodgkin Lymphome aus. Männer sind häufiger betroffen als Frauen. Der Anspruch systemischer Primärtherapie ist kurativ, wobei generell in ca. 30% der Fälle ein primär refraktärer Verlauf zu beobachten ist. Das Ansprechen auf eine Folgetherapie ist meist schlecht, weswegen eine Behandlung in Studien zu empfehlen ist.
Subject code	610
Language	German
Size	1 Online-Ressource (18 Seiten), Diagramme
Edition	Stand: September 2019
Publisher	DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V
Publishing place	Berlin
Publishing country	Germany
Document type	Book ; Online
HBZ-ID	HT020611424
DOI	10.4126/FRL01-006423414
Database	Repository for Life Sciences

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Book ; Online: Periphere T-Zell Lymphome

Hopfinger, Georg / Krasniqi, Fatime / Reimer, Peter / Schmitz, Norbert / Wulf, Gerald

Leitlinie : ICD10: C84.- : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen

(Onkopedia Leitlinien)

2016

Institution	Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie Schweizerische Gesellschaft für Hämatologie
Author's details	Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Österreichische Gesellschaft für Hämatologie & Medizinische Onkologie, SGH/SSH ; Autoren: Georg Hopfinger, Fatime Krasniqi, Peter Reimer, Norbert Schmitz, Gerald Wulf
Series title	Onkopedia Leitlinien
Subject code	610
Language	German
Size	1 Online-Ressource (18 Seiten)
Edition	Stand: März 2016
Publisher	DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V
Publishing place	Berlin
Publishing country	Germany
Document type	Book ; Online
HBZ-ID	HT019070078
DOI	10.4126/FRL01-006400561
Database	Repository for Life Sciences

Full text online

Full text

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Knochensarkome – Diagnostik und Therapie

Barlow, Kira A. / Krieg, Andreas H. / Krasniqi, Fatime

TumorDiagnostik & Therapie

2024 Volume 45, Issue 04, Page(s) 234–238

Keywords	Osteosarkom ; Knochensarkom ; Chondrosarkom ; Ewing-Sarkom
Language	German
Publishing date	2024-05-01
Publisher	Georg Thieme Verlag KG
Publishing place	Stuttgart ; New York
Document type	Article
ZDB-ID	2072365-9
ISSN	1439-1279 ; 0722-219X
ISSN (online)	1439-1279
ISSN	0722-219X
DOI	10.1055/a-2226-1202
Database	Thieme publisher's database

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Synovial sarcoma: the misdiagnosed sarcoma.

Li, Chengxiang / Krasniqi, Fatime / Donners, Ricardo / Kettelhack, Christoph / Krieg, Andreas H

EFORT open reviews

2024 Volume 9, Issue 3, Page(s) 190–201

Abstract: Synovial sarcoma is a rare and highly malignant soft tissue sarcoma. The inconspicuous and diversity of its early symptoms make it a highly misdiagnosed disease. The management of synovial sarcomas is challenging as they are rare and have a poor ... ...

Abstract	Synovial sarcoma is a rare and highly malignant soft tissue sarcoma. The inconspicuous and diversity of its early symptoms make it a highly misdiagnosed disease. The management of synovial sarcomas is challenging as they are rare and have a poor prognosis. Early and correct diagnosis and treatment are critical for clinical outcomes. Misdiagnosis or delayed diagnosis can have devastating consequences for the patient. The detection of SS18 gene rearrangement is considered a powerful tool in establishing the diagnosis of synovial sarcomas. Biopsies and testing for gene rearrangements are recommended for all patients in whom SS cannot be excluded. Surgery is the mainstay of treatment for synovial sarcomas. Neoadjuvant/adjuvant radiotherapy is recommended for patients with big tumors (>5 cm) or positive resection margins, and neoadjuvant/adjuvant chemotherapy is recommended for patients with high-risk tumors or advanced diseases. This article reviews synovial sarcomas from the perspectives of clinical and radiological presentation, histological and cytogenetic analysis, differential diagnosis, treatment, and prognosis.
Language	English
Publishing date	2024-03-05
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2844421-8
ISSN	2058-5241 ; 2058-5241 ; 2396-7544
ISSN (online)	2058-5241
ISSN	2058-5241 ; 2396-7544
DOI	10.1530/EOR-23-0193
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Case report: 'Atypical Richter transformation from CLL-type monoclonal B-cell lymphocytosis into Burkitt lymphoma in a treatment naïve patient'.

Jauch, Annaïse J / Alborelli, Ilaria / Reusser, Andreas / Baschong, Albert / Rütsche, Cyrill / Bignucolo, Olivier / Passweg, Jakob / Dirnhofer, Stefan / Krasniqi, Fatime

Frontiers in oncology

2024 Volume 14, Page(s) 1296238

Abstract: Background: Richter transformation refers to the progression of an initially slow-growing small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) into an aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma.! ...

Abstract	Background: Richter transformation refers to the progression of an initially slow-growing small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) into an aggressive lymphoma, typically diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma. Case presentation: The patient presented with a rapid onset of localized cervical swelling, accompanied by monoclonal B-cell lymphocytosis displaying a CLL immunophenotype. The histopathological analysis identified a Burkitt lymphoma (BL) located in the submandibular gland and adjacent lymph node. The patient's bone marrow displayed a minor infiltration of monoclonal B-cells with a CLL immunophenotype (< 10%). Molecular analysis demonstrated the presence of the same monoclonal rearrangement in the framework region (FR3 region) of the immunoglobulin heavy chain ( Conclusion: This report provides an exceptionally rare description of a CLL-type monoclonal B-cell lymphocytosis transforming into a very aggressive Burkitt lymphoma in a treatment naïve patient.
Language	English
Publishing date	2024-05-03
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2649216-7
ISSN	2234-943X
ISSN	2234-943X
DOI	10.3389/fonc.2024.1296238
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: 9th Annual T-Cell Lymphoma Forum, January 26-28, 2017, San Francisco (CA), USA

Krasniqi, F. / Zucca, E.

Schweizer Krebs-Bulletin

2017 Volume 37, Issue 2, Page(s) 209–211

Language	English ; French ; German
Document type	Article
ZDB-ID	1340924-4
Database	Current Contents Medicine

In stock of ZB MED Cologne/Königswinter

Zs.A 4528: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.

Digklia, A / Kollár, A / Dietrich, D / Kronig, M N / Britschgi, C / Rordorf, T / Joerger, M / Krasniqi, F / Metaxas, Y / Colombo, I / Ribi, K / Rothermundt, C

European journal of cancer (Oxford, England : 1990)

2023 Volume 197, Page(s) 113470

Abstract: Background: To determine whether the combination of nab-paclitaxel with gemcitabine has activity in patients with pretreated soft tissue sarcoma (STS).: Patients and methods: NAPAGE is a phase Ib/II clinical trial investigating the combination of nab- ...

Abstract	Background: To determine whether the combination of nab-paclitaxel with gemcitabine has activity in patients with pretreated soft tissue sarcoma (STS). Patients and methods: NAPAGE is a phase Ib/II clinical trial investigating the combination of nab-paclitaxel (nab-pc) with gemcitabine employing two cohorts. One of a dose-de-escalation phase and one of expansion. In phase I, nab-pc was given at 150 mg/m Results: The 3-month PFR was 56.4% (95% confidence interval CI: 39.6-72.2%). The 3-month and 6-month PFS were 58.4% (95% CI: 41.3-72.1%) and 44.6% (95% CI: 28.4-59.5%), respectively. Median PFS was 5.3 months (95% CI: 1.4-8.2) and median OS was 12.8 months (95% CI: 10.5-39.2). The most common treatment-related grade ≥ 3 AE were neutropenia (18%), followed by anemia (2.6%), hypertension (2.6%) and alanine aminotransferase increase (2.6%). Grade 1 and grade 2 peripheral sensory neuropathy (PNP) occurred in 15.4% and 20.5%, respectively. No grade 3-4 PNP was reported. Conclusions: Combining nab-pc and gemcitabine is safe. Promising activity is observed in pretreated STS patients with manageable toxicity. This regimen should be considered for further exploration.
MeSH term(s)	Humans ; Albumins ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deoxycytidine/therapeutic use ; Gemcitabine ; Paclitaxel/therapeutic use ; Pancreatic Neoplasms/drug therapy ; Sarcoma/drug therapy ; Treatment Outcome
Chemical Substances	130-nm albumin-bound paclitaxel ; Albumins ; Deoxycytidine (0W860991D6) ; Gemcitabine ; Paclitaxel (P88XT4IS4D)
Language	English
Publishing date	2023-12-09
Publishing country	England
Document type	Clinical Trial, Phase II ; Clinical Trial, Phase I ; Journal Article
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2023.113470
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾

Article: Ipilimumab and Pembrolizumab Mixed Response in a 41-Year-Old Patient with SMARCA4-Deficient Thoracic Sarcoma: An Interdisciplinary Case Study.

Anžič, Nina / Krasniqi, Fatime / Eberhardt, Anna-Lena / Tzankov, Alexandar / Haslbauer, Jasmin Dionne

Case reports in oncology

2021 Volume 14, Issue 2, Page(s) 706–715

Abstract: SMARCA4-deficient thoracic sarcoma is a newly described entity of thoracic sarcomas with a poor prognosis, defined by poorly differentiated epithelioid to rhabdoid histomorphology and SMARCA4 gene inactivation. We present a case of a SMARCA4-deficient ... ...

Abstract	SMARCA4-deficient thoracic sarcoma is a newly described entity of thoracic sarcomas with a poor prognosis, defined by poorly differentiated epithelioid to rhabdoid histomorphology and SMARCA4 gene inactivation. We present a case of a SMARCA4-deficient thoracic sarcoma in a 41-year-old male with a smoking history who presented with an upper anterior mediastinal mass, after seeking medical evaluation for increasing thoracic pain, odynophagia, and dizziness. The biopsy confirmed a large cell tumor with an epithelioid to rhabdoid histomorphology, positive for EMA, CD99, vimentin, TLE1, INI1, PAS-positive cytoplasmic granules, and PD-L1 (100% of tumor cells). High TMB and HRD scores were displayed in the tumor. The histology and immunophenotype of the mass were in line with the diagnosis of SMARCA4-deficient thoracic sarcoma. In the course of his treatment, the patient showcased a partial response to pembrolizumab and the combination of pembrolizumab and ipilimumab. This case report highlights the importance of recognizing SMARCA4-deficient thoracic sarcoma as an individual entity and supports the importance of checkpoint inhibition therapy for SMARCA4-deficient thoracic sarcomas, particularly in cases with a high TMB and PD-L1 expression.
Language	English
Publishing date	2021-05-10
Publishing country	Switzerland
Document type	Case Reports
ZDB-ID	2458961-5
ISSN	1662-6575
ISSN	1662-6575
DOI	10.1159/000515416
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Impact of individualized treatment on recovery from fatigue and return to work in survivors of advanced-stage Hodgkin's lymphoma: results from the randomized international GHSG HD18 trial.

Ferdinandus, J / Müller, H / Damaschin, C / Jacob, A S / Meissner, J / Krasniqi, F / Mey, U / Schöndube, D / Thiemer, J / Mathas, S / Zijlstra, J / Greil, R / Feuring-Buske, M / Markova, J / Rüffer, J U / Kobe, C / Eich, H-T / Baues, C / Fuchs, M /

Borchmann, P / Behringer, K

Annals of oncology : official journal of the European Society for Medical Oncology

2023 Volume 35, Issue 3, Page(s) 276–284

Abstract: Background: Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin's lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by ... ...

Abstract	Background: Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin's lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-2) as new standard. Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time to recovery from fatigue (TTR-F), and time to return to work (TTR-W). Patients and methods: Patients received European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and life situation questionnaires at baseline, interim, end of treatment, and yearly follow-up. TTR-F was defined as time from the end of chemotherapy until the first fatigue score <30. TTR-W was analyzed in previously working or studying patients and measured from the end of treatment until the first documented work or education. We compared duration of treatment on TTR-F and TTR-W using Cox proportional hazards regression adjusted for confounding variables. Results: HRQoL questionnaires at baseline were available in 1632 (83.9%) of all randomized patients. Overall, higher baseline fatigue and age were significantly associated with longer TTR-F and TTR-W and male sex with shorter TTR-W. Treatment reduction from eight to four chemotherapy cycles led to a significantly shorter TTR-F [hazard ratio (HR) 1.41, P = 0.008] and descriptively shorter TTR-W (HR 1.24, P = 0.084) in PET-2-negative patients. Reduction from six to four cycles led to non-significant but plausible intermediate accelerations. The addition of rituximab caused significantly slower TTR-F (HR 0.70, P = 0.0163) and TTR-W (HR 0.64, P = 0.0017) in PET-2-positive patients. HRQoL at baseline and age were the main determinants of 2-year HRQoL. Conclusions: Individualized first-line treatment in patients with advanced-stage HL considerably shortens TTR-F and TTR-W in PET-2-negative patients. Our results support the use of response-adapted shortened treatment duration for patients with HL.
MeSH term(s)	Humans ; Male ; Hodgkin Disease/pathology ; Quality of Life ; Return to Work ; Fatigue/etiology ; Survivors ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Language	English
Publishing date	2023-12-05
Publishing country	England
Document type	Journal Article
ZDB-ID	1025984-3
ISSN	1569-8041 ; 0923-7534
ISSN (online)	1569-8041
ISSN	0923-7534
DOI	10.1016/j.annonc.2023.11.014
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2862: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

Kategorien

Inter-library loan at ZB MED

Full text online

Kategorien

Inter-library loan at ZB MED

Full text online

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito